AtriCureATRC -0.63%76 FCF Margin % is -5.56% as of Mar. 2026. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.73 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, AtriCure ranks better than 69.94% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AtriCure's Free Cash Flow for the
three
months ended in Mar. 2026 was $-7.8 Mil. AtriCure's Revenue for the
three
months ended in Mar. 2026 was $141.2 Mil. Therefore, AtriCure's FCF Margin % for the quarter that ended in Mar. 2026 was -5.56%.
The historical rank and industry rank for AtriCure's FCF Margin % or its related term are showing as below:
ATRC'
s FCF Margin % Range Over the Past 10 Years
Min: -14.71 Med: -9.09 Max: 8.63
Current: 8.63
During the past 13 years, the highest FCF Margin % of AtriCure was 8.63%. The lowest was -14.71%. And the median was -9.09%.
ATRC's FCF Margin % is ranked better than 69.94% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs ATRC: 8.63
AtriCure FCF Margin % Related Terms
AtriCure FCF Margin % Historical Data
* Premium members only.
The historical data trend for AtriCure's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AtriCure's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's FCF Margin % distribution charts can be found below:
* The bar in red indicates where AtriCure's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure (ATRC) has a FCF Margin % of -5.56% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on AtriCure and its competitors. According to the industry distribution chart, AtriCure ranks #245 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 30.1%.
Is AtriCure's FCF Margin % too high?
AtriCure's current FCF Margin % is -5.56%. Based on the distribution chart, AtriCure ranks #245 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's FCF Margin % compare to STAA and NNNN?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #245 out of 815 companies for FCF Margin %. This puts AtriCure in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on AtriCure and its competitors. AtriCure's current FCF Margin % is -5.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.73, compared to a current price of $28.26 — trading 28.9% below its estimated fair value. The current FCF Margin % is -5.56%. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For AtriCure (ATRC), the current FCF Margin % is -5.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (ATRC) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be undervalued.
The current stock price of $28.26 is trading 28.9% below its estimated GF Value™ of $39.73.
GuruFocus considers AtriCure to be Modestly Undervalued.
Key valuation signals for ATRC:
FCF Margin %: -5.56%
GF Value™: $39.73 vs. price of $28.26 (28.9% below fair value)
No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
76GF Score
Get the complete analysis for ATRC
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRC has been successfully added to your 
